BW-20507 with/without NUC
Phase 2Small molecule
BW-20507 with/without NUC is one of 30 small molecule programs targeting Hepatitis B. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
252 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1YF-Vax
SanofiPhase 3
Virazole
CConrado Roberto Hoffmann Filho
Phase 3
Immunoglobulins
CSL BehringPhase 3
Recombinant Hepatitis B Vaccine
NovartisPhase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Hepatitis B Adjuvanted Vaccine
GSKPhase 3
HEPLISAV
DDynavax Technologies Corporation
Phase 3
Vemlidy
GileadPreclinical
HB-AS02V
HHenogen
Phase 3
HBVAXPRO Vaccine
HHenogen
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BW-20507 with/without NUC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details